Morosini Deborah 4

4 · Prelude Therapeutics Inc · Filed Dec 17, 2021

Form 4

Period: 2021-12-15

EVP, Chief of Clinical Affairs

Transactions

Exercise/Conversion
Common Stock
2021-12-15$12.85/sh+25,735$330,695→ 29,195 total
Sale
Common Stock
2021-12-15$13.00/sh−28,751$373,763→ 444 total
Exercise/Conversion
Employee Stock Option (right to buy)
2021-12-15−3,016→ 1,307 total
Exercise: $1.89Exp: 2030-03-26→ Common Stock (3,016 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2021-12-15−882→ 195,163 total
Exercise: $12.85Exp: 2030-09-01→ Common Stock (882 underlying)
Exercise/Conversion
Common Stock
2021-12-15$1.89/sh+3,016$5,700→ 3,460 total
Exercise/Conversion
Employee Stock Option (right to buy)
2021-12-15−24,853→ 74,575 total
Exercise: $12.85Exp: 2030-09-01→ Common Stock (24,853 underlying)

Footnotes (4)

[F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
[F2]The stock option is fully vested.
[F3]The stock option vests as to 25% of the total shares monthly beginning on September 24, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
[F4]The stock option vests as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

Documents

1 file